Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.
